Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554634 | 0.85 | DDB1 (0.49) | DDB1CRBNIKZF3HCAR1CYP11B2 | |
| SCHEMBL22557583 | 0.84 | CRBN (0.41) | DDB1CRBNIKZF3 | |
| SCHEMBL31620115 | 0.83 | DDB1 (0.56) | DDB1CRBNIKZF3HCAR1GPR119 | |
| SCHEMBL22557788 | 0.81 | CRBN (0.49) | DDB1CRBNIKZF3 | |
| SCHEMBL20231710 | 0.79 | CRBN (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL29369875 | 0.79 | CRBN (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL29579621 | 0.78 | DDB1 (0.48) | DDB1CRBNGPR119 | |
| SCHEMBL22291548 | 0.77 | CRBN (0.46) | DDB1CRBNGPR119 | |
| SCHEMBL20234853 | 0.77 | CRBN (0.52) | DDB1CRBNIKZF3 | |
| SCHEMBL31727669 | 0.77 | CRBN (0.52) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825657-A | Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof | 成都海创药业有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |